List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3282908/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Nonparametric Methods in Population Pharmacokinetics. Journal of Clinical Pharmacology, 2022, 62, 142-157.	2.0	28
2	Parametric and Nonparametric Methods in Population Pharmacokinetics: Experts' Discussion on Use, Strengths, and Limitations. Journal of Clinical Pharmacology, 2022, 62, 158-170.	2.0	9
3	Therapeutic Drug Monitoring of Antibiotic Drugs in Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis: A Critical Review. Therapeutic Drug Monitoring, 2022, 44, 86-102.	2.0	10
4	Pharmacokinetic/Pharmacodynamic Simulations of Cost-Effective Dosage Regimens of Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Patients with Renal Impairment. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0210421.	3.2	2
5	Implementation and Comparison of Two Pharmacometric Tools for Model-Based Therapeutic Drug Monitoring and Precision Dosing of Daptomycin. Pharmaceutics, 2022, 14, 114.	4.5	8
6	Cefepime Precision Dosing Tool: from Standard to Precise Dose Using Nonparametric Population Pharmacokinetics. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0204621.	3.2	9
7	Subcutaneous Antibiotic Therapy: The Why, How, Which Drugs and When. Journal of the American Medical Directors Association, 2021, 22, 50-55.e6.	2.5	20
8	Drug interactions between emergency contraceptive drugs and cytochrome inducers: literature review and quantitative prediction. Fundamental and Clinical Pharmacology, 2021, 35, 208-216.	1.9	2
9	Population pharmacokinetics of daptomycin in patients with bone and joint infection: minimal effect of rifampicin co-administration and confirmation of a sex difference. Journal of Antimicrobial Chemotherapy, 2021, 76, 1250-1257.	3.0	9
10	Pharmacokinetic/Pharmacodynamic Dosage Individualization of Suppressive Beta-Lactam Therapy Administered by Subcutaneous Route in Patients With Prosthetic Joint Infection. Frontiers in Medicine, 2021, 8, 583086.	2.6	7
11	Rifampicin exposure reveals within-host Mycobacterium tuberculosis diversity in patients with delayed culture conversion. PLoS Pathogens, 2021, 17, e1009643.	4.7	10
12	Safety of Tedizolid as Suppressive Antimicrobial Therapy for Patients With Complex Implant-Associated Bone and Joint Infection due to Multidrug-Resistant Gram-Positive Pathogens: Results From the TediSAT Cohort Study. Open Forum Infectious Diseases, 2021, 8, ofab351.	0.9	4
13	To Estimate or to Forecast? Lessons From a Comparative Analysis of Four Bayesian Fitting Methods Based on Nonparametric Models. Therapeutic Drug Monitoring, 2021, 43, 461-471.	2.0	4
14	Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile. Antimicrobial Agents and Chemotherapy, 2021, 65, e0104321.	3.2	13
15	Population Pharmacokinetic Modeling and Dosing Simulations of Tobramycin in Pediatric Patients with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0073721.	3.2	5
16	Amikacin in emergency surgery: how to dose it optimally?. Anaesthesia, Critical Care & Pain Medicine, 2021, 41, 100990.	1.4	1
17	Quantitative Prediction of Interactions Mediated by Transporters and Cytochromes: Application to Organic Anion Transporting Polypeptides, Breast Cancer Resistance Protein and Cytochrome 2C8. Clinical Pharmacokinetics, 2020, 59, 757-770.	3.5	5
18	A Population Pharmacokinetic Analysis of Continuous Infusion of Cloxacillin during <i>Staphylococcus aureus</i> Bone and Joint Infections. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	8

#	Article	IF	CITATIONS
19	Outpatient Subcutaneous Antimicrobial Therapy (OSCAT) as a Measure to Improve the Quality and Efficiency of Healthcare Delivery for Patients With Serious Bacterial Infections. Frontiers in Medicine, 2020, 7, 585658.	2.6	7
20	Tolerance and microbiological efficacy of cefepime or piperacillin/tazobactam in combination with vancomycin as empirical antimicrobial therapy of prosthetic joint infection: a propensity-matched cohort study. Journal of Antimicrobial Chemotherapy, 2020, 75, 2299-2306.	3.0	5
21	Azithromycin for COVID-19: More Than Just an Antimicrobial?. Clinical Drug Investigation, 2020, 40, 683-686.	2.2	83
22	Intra-individual Pharmacokinetic Variability of Intravenous Busulfan in Hematopoietic Stem Cell-Transplanted Children. Clinical Pharmacokinetics, 2020, 59, 1049-1061.	3.5	18
23	Medical innovations to maintain the function in patients with chronic PJI for whom explantation is not desirable: a pathophysiology-, multidisciplinary-, and experience-based approach. Sicot-j, 2020, 6, 26.	1.8	9
24	Goal-Oriented Monitoring of Cyclosporine Is Effective for Graft-versus-Host Disease Prevention after Hematopoietic Stem Cell Transplantation in Sickle Cell Disease and Thalassemia Major. Biology of Blood and Marrow Transplantation, 2020, 26, 2285-2291.	2.0	3
25	Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children. Bone Marrow Transplantation, 2019, 54, 448-457.	2.4	31
26	Genetic polymorphisms of ABCB1 (P-glycoprotein) as a covariate influencing daptomycin pharmacokinetics: a population analysis in patients with bone and joint infection. Journal of Antimicrobial Chemotherapy, 2019, 74, 1012-1020.	3.0	12
27	Amikacin Initial Dose in Critically III Patients: a Nonparametric Approach To Optimize <i>A Priori</i> Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	16
28	Subcutaneous suppressive antibiotic therapy for bone and joint infections: safety and outcome in a cohort of 10 patients. Journal of Antimicrobial Chemotherapy, 2019, 74, 2060-2064.	3.0	15
29	Optimization of the treatment with beta-lactam antibiotics in critically ill patients—guidelines from the French Society of Pharmacology and Therapeutics (Société Fran§aise de Pharmacologie et) Tj ETQq1 :	I 0. <u>78</u> 4314	4 rgBT /Overlo
30	Determinants of amikacin first peak concentration in critically ill patients. Fundamental and Clinical Pharmacology, 2018, 32, 669-677.	1.9	5
31	Comment on: MIC-based dose adjustment: facts and fables. Journal of Antimicrobial Chemotherapy, 2018, 73, 2584-2585.	3.0	7
32	Population pharmacokinetics and probability of target attainment of ertapenem administered by subcutaneous or intravenous route in patients with bone and joint infection. Journal of Antimicrobial Chemotherapy, 2018, 73, 987-994.	3.0	19
33	Identification of Cytochrome P450-Mediated Drug–Drug Interactions at Risk in Cases of Gene Polymorphisms by Using a Quantitative Prediction Model. Clinical Pharmacokinetics, 2018, 57, 1581-1591.	3.5	8
34	Assessing the Combined Antibacterial Effect of Isoniazid and Rifampin on Four Mycobacterium tuberculosis Strains Using <i>In Vitro</i> Experiments and Response-Surface Modeling. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	9
35	Correction of Linezolid-Induced Myelotoxicity After Switch to Tedizolid in a Patient Requiring Suppressive Antimicrobial Therapy for Multidrug-Resistant Staphylococcus epidermidis Prosthetic-Joint Infection. Open Forum Infectious Diseases, 2018, 5, ofy246.	0.9	16
36	Antituberculous drugs modulate bacterial phagolysosome avoidance and autophagy in Mycobacterium tuberculosis-infected macrophages. Tuberculosis, 2018, 111, 67-70.	1.9	24

#	Article	IF	CITATIONS
37	Prospective Cohort Study of the Tolerability of Prosthetic Joint Infection Empirical Antimicrobial Therapy. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	13
38	Population Pharmacokinetic Study of Amoxicillin-Treated Burn Patients Hospitalized at a Swiss Tertiary-Care Center. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	9
39	Mechanisms of drug–drug interaction between rifampicin and fusidic acid. British Journal of Clinical Pharmacology, 2017, 83, 1862-1864.	2.4	4
40	Prevalence and Risk Factors of Drug-Associated Corrected QT Prolongation in Elderly Hospitalized Patients: Results of a Retrospective Analysis of Data Obtained Over 6AMonths. Drugs and Aging, 2017, 34, 545-553.	2.7	5
41	A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics. Clinical Pharmacokinetics, 2017, 56, 435-447.	3.5	11
42	Implications of using the <scp>MDRD</scp> or <scp>CKD</scp> â€ <scp>EPI</scp> equationÂinstead of the Cockcroft–Gault equationÂfor estimating renal function and drug dosage adjustment in elderly patients. Fundamental and Clinical Pharmacology, 2017, 31, 110-119.	1.9	24
43	Comparison of the static <i>in vivo</i> approach to a physiologically based pharmacokinetic approach for metabolic drug–drug interactions prediction. International Journal of Pharmacokinetics, 2016, 1, 25-34.	0.5	10
44	Bayesian network to optimize the first dose of antibiotics: application to amikacin. International Journal of Pharmacokinetics, 2016, 1, 35-42.	0.5	4
45	Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software. Therapeutic Drug Monitoring, 2016, 38, 332-342.	2.0	53
46	Mathematical modeling and systems pharmacology of tuberculosis: Isoniazid as a case study. Journal of Theoretical Biology, 2016, 399, 43-52.	1.7	9
47	Pharmacokinetic Variability of Daptomycin during Prolonged Therapy for Bone and Joint Infections. Antimicrobial Agents and Chemotherapy, 2016, 60, 3148-3151.	3.2	19
48	Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers. Clinical Pharmacokinetics, 2016, 55, 977-990.	3.5	23
49	Quantitative Methods for Prediction of the Effect of Cytochrome P450 Gene Polymorphisms on Substrate Drug Exposure. Clinical Pharmacokinetics, 2015, 54, 319-320.	3.5	Ο
50	A pharmacometric pulmonary model predicting the extent and rate of distribution from plasma to epithelial lining fluid and alveolar cells—using rifampicin as an example. European Journal of Clinical Pharmacology, 2015, 71, 313-319.	1.9	14
51	A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child–Pugh Classification. Clinical Pharmacokinetics, 2015, 54, 1245-1258.	3.5	14
52	Influence of Renal Function Estimation on Pharmacokinetic Modeling of Vancomycin in Elderly Patients. Antimicrobial Agents and Chemotherapy, 2015, 59, 2986-2994.	3.2	20
53	Pharmacokinetic Drug Interaction Between Cyclosporine and Imatinib in Bone Marrow Transplant Children and Model-Based Reappraisal of Imatinib Drug Interaction Profile. Therapeutic Drug Monitoring, 2014, 36, 724-729.	2.0	10
54	Determinants of Torsades de Pointes in Older Patients with Drug-Associated Long QT Syndrome: A Case-Control Study. Drugs and Aging, 2014, 31, 601-609.	2.7	11

#	Article	IF	CITATIONS
55	The Case for Using Higher Doses of First Line Anti-Tuberculosis Drugs to Optimize Efficacy. Current Pharmaceutical Design, 2014, 20, 6191-6206.	1.9	11
56	In Vivo Quantitative Prediction of the Effect of Gene Polymorphisms and Drug Interactions on Drug Exposure for CYP2C19 Substrates. AAPS Journal, 2013, 15, 415-426.	4.4	39
57	Pharmacokinetic-Pharmacodynamic Modeling of Unboosted Atazanavir in a Cohort of Stable HIV-Infected Patients. Antimicrobial Agents and Chemotherapy, 2013, 57, 517-523.	3.2	14
58	Comparison of Four Renal Function Estimation Equations for Pharmacokinetic Modeling of Gentamicin in Geriatric Patients. Antimicrobial Agents and Chemotherapy, 2012, 56, 1862-1869.	3.2	28
59	The value of population pharmacokinetics and simulation for postmarketing safety evaluation of dosing guidelines for drugs with a narrow therapeutic index: buflomedil as a case study. Fundamental and Clinical Pharmacology, 2012, 26, 279-285.	1.9	10
60	Quantitative Prediction of Cytochrome P450 (CYP) 2D6-Mediated Drug Interactions. Clinical Pharmacokinetics, 2011, 50, 519-530.	3.5	43
61	Mathematical modeling of pulmonary tuberculosis therapy: Insights from a prototype model with rifampin. Journal of Theoretical Biology, 2011, 282, 80-92.	1.7	24
62	Oral Voriconazole Dose in Children: One Size Does Not Fit All. Clinical Infectious Diseases, 2010, 51, 870-870.	5.8	10
63	Population Modeling and Monte Carlo Simulation Study of the Pharmacokinetics and Antituberculosis Pharmacodynamics of Rifampin in Lungs. Antimicrobial Agents and Chemotherapy, 2009, 53, 2974-2981.	3.2	96
64	Visual estimation of patients' body weight in hospital: the more observers, the better?. International Journal of Clinical Pharmacy, 2009, 31, 422-425.	1.4	11
65	The Hill equation: a review of its capabilities in pharmacological modelling. Fundamental and Clinical Pharmacology, 2008, 22, 633-648.	1.9	645